Compare Mutual Funds

Insights from Fund Comparison

• Both Nippon India Pharma Fund (IDCW) and WhiteOak Capital Pharma and Healthcare Fund-Dir (G) are Sectoral / Thematic, Equity schemes. Nippon India Pharma Fund (IDCW) is 21 yrs 10 m old and manages ₹8,306.35 Crs, whereas WhiteOak Capital Pharma and Healthcare Fund-Dir (G) is 2 yrs 2 m old with ₹533.05 Crs.
• Nippon India Pharma Fund (IDCW) is therefore older and larger, which may indicate more experience and investor confidence.
• Nippon India Pharma Fund (IDCW) has its top 3 sectors in Pharmaceuticals (73.95%), Healthcare (20.31%), and Retail (3.70%), while WhiteOak Capital Pharma and Healthcare Fund-Dir (G) focuses on Pharmaceuticals (57.67%), Healthcare (25.98%), and Pharmaceuticals & Biotechnology (3.72%).
• The funds share exposure to Pharmaceuticals and Healthcare, but differ in the rest, which means they will partially move together but may diverge depending on how the unique sectors perform.
• Nippon India Pharma Fund (IDCW) holds Sun Pharmaceutical Industries Limited (13.08%), Lupin Limited (7.99%), Divi's Laboratories Limited (6.56%), Dr. Reddy's Laboratories Limited (5.81%), and Cipla Limited (5.67%), whereas WhiteOak Capital Pharma and Healthcare Fund-Dir (G) holds Sun Pharmaceutical Industries Limited (11.85%), JB Chemicals & Pharmaceuticals Limited (9.44%), Max Healthcare Institute Limited (5.88%), Fortis Healthcare Limited (5.54%), and Lupin Limited (5.29%).
• The funds share exposure to Sun Pharmaceutical Industries Limited and Lupin Limited, which makes their performance partly correlated. However, the unique holdings like Divi's Laboratories Limited in Nippon India Pharma Fund (IDCW) and JB Chemicals & Pharmaceuticals Limited in WhiteOak Capital Pharma and Healthcare Fund-Dir (G) can create divergence depending on how these stocks perform.
• In terms of risk profile, Nippon India Pharma Fund (IDCW) has 99.68% equity and 0.00% debt, while WhiteOak Capital Pharma and Healthcare Fund-Dir (G) has 93.86% equity and 2.42% debt.
• Nippon India Pharma Fund (IDCW) is more aggressive with higher equity allocation, which could lead to higher returns but more volatility.
• Nippon India Pharma Fund (IDCW) showed short-term strength over 3 Months, 6 Months (returns: -6.29%, -3.74%), outperforming WhiteOak Capital Pharma and Healthcare Fund-Dir (G) by 1.38%, 0.64%. However, other periods (1 Year, 3 Years, 5 Years, returns: 3.66%, 20.92%, 13.51% ) lagged behind, suggesting this could be a temporary upswing. Monitor for sustained momentum before making long-term decisions.